|Year : 2021 | Volume
| Issue : 3 | Page : 456-458
Zosteriform-fixed drug eruption secondary to ciprofloxacin
Ravi Bhushan, Bhagyashree B Supekar, Jayesh Mukhi, Rajesh P Singh
Department of Dermatology, Venereology and Leprology, Government Medical College and Hospital, Nagpur, Maharashtra, India
|Date of Submission||10-Jun-2020|
|Date of Decision||28-Jul-2020|
|Date of Acceptance||13-Sep-2020|
|Date of Web Publication||12-May-2021|
Bhagyashree B Supekar
Senior Resident, Department of Dermatology, Venereology and Leprology, Government Medical College and Hospital, Nagpur - 440 003, Maharashtra
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bhushan R, Supekar BB, Mukhi J, Singh RP. Zosteriform-fixed drug eruption secondary to ciprofloxacin. Indian Dermatol Online J 2021;12:456-8
|How to cite this URL:|
Bhushan R, Supekar BB, Mukhi J, Singh RP. Zosteriform-fixed drug eruption secondary to ciprofloxacin. Indian Dermatol Online J [serial online] 2021 [cited 2022 Jan 25];12:456-8. Available from: https://www.idoj.in/text.asp?2021/12/3/456/308912
Ciprofloxacin is a broad-spectrum quinolone antibiotic, active against gram-positive and negative microorganisms with easy dosing and good tolerability. It is commonly associated with nondermatological adverse drug reactions (ADRs) such as mild nausea, vomiting, abdominal discomfort, headache, dizziness etc. The dermatological ADRs that have been described are morbilliform rash, photosensitivity, urticaria, angioedema, and rarely fixed drug eruptions (FDEs)., To the best of our knowledge, this is the first instance of the development of isolated zosteriform fixed drug eruption secondary to ciprofloxacin.
A 46-year-old male, presented to us with multiple dark-colored raised lesion on the left side of chest and back since four days, associated with mild itching and burning sensation. He had a history of acute kidney injury five days back, for which he was being treated with 500 mg of tablet ciprofloxacin twice a day. The patient developed skin lesions one day after ciprofloxacin ingestion. The patient denied any history of similar complaints in the past or any topical application. On examination, there were multiple well-defined erythematous to violaceous patches with bullae at few areas distributed over the left side of chest [Figure 1]a and [Figure 1]b, axilla [Figure 1]c, and back [Figure 1]d in a linear fashion. Rest cutaneous examination and general and systemic examinations were normal. Based on history and clinical examination, differential diagnoses of herpes zoster and zosteriform FDE were considered. Routine hematological investigations were normal. No multinucleated giant cells were demonstrated on tzanck smear. Histopathology from the bullous lesion over chest revealed intraepidermal separation, vacuolar alteration of basal cell layer [Figure 2]a, and inflammatory infiltrate in dermis suggestive of bullous FDE [Figure 2]b. Based on the history, clinical examination, and histopathological findings, a diagnosis of ciprofloxacin-induced zosteriform bullous FDE was reached. This case was reported to the pharmacovigilance programme of India (PVPI) (report no. 2019-53787). Based on the Naranjo scale, this ADR was considered as probable. He was advised to discontinue ciprofloxacin and cutaneous lesions were treated with topical steroid-antibiotic preparation. There was complete resolution of cutaneous lesions over the left side of the chest [Figure 3]a and [Figure 3]b, axilla [Figure 3]c, and back [Figure 3]d after seven days of treatment.
|Figure 1: (a-d): Multiple well-defined erythematous to violaceous patches with bullae at few areas distributed over the left side of chest (a and b); axilla (c), and back (d) in a linear fashion|
Click here to view
|Figure 2: (a and b): Histopathology from the bullous lesion over chest revealed intraepidermal separation, vacuolar alteration of basal cell layer (a) and inflammatory infiltrate in dermis (b) suggestive of bullous fixed drug eruption (H and E a: 10×; b: 40×)|
Click here to view
|Figure 3: (a-d): Complete resolution of cutaneous lesions over the left side of chest (a and b), axilla (c), and back (d) after seven days of treatment|
Click here to view
Brocq was the first to use the term FDE in 1894. It is a delayed-type hypersensitivity characterized by the sudden onset of edematous, dusky-red macules/plaque on the skin and/or mucous membranes. Some antibacterials (sulfonamides, tetracycline, and minocycline), antipsychotics, analgesics, and rarely quinolones are known to develop fixed drug eruption. Ciprofloxacin is a broad-spectrum quinolone antibiotic widely used for infection of the respiratory tract, urinary tract, bones, and soft tissues. The cutaneous ADRs are reported in 1–2% of patients after treatment with ciprofloxacin. The dermatological ADRs that have been commonly documented are morbiliform rash, photosensitivity, urticarial, and angioedema. Rarely, it can also cause erythema multiforme, SJS, vasculitis, and FDE.,,,, The first case of FDE due to ciprofloxacin was reported in a 35-year-old Japanese male by Kawade in 1994. Ciprofloxacin-induced bullous FDE was first reported in India by Bose. Later in 1995, Sohar reported a series of seven cases of nonbullous FDE secondary to ciprofloxacin over two years. Nonbullous, generalized, bullous, and pigmented FDE have been rarely reported with ciprofloxacin [Table 1].,,,, Our patient had bullous FDE in a dermatomal distribution (T3-T4), which is reported rarely in the literature. Most FDE occur within 30 min to 1 day of exposure, as seen in our patient who developed FDE one day after ingestion of ciprofloxacin. In our case, adult blaschkitis was ruled out based on the acute onset of lesions, temporal association with drug, and histopathological findings. Zosteriform FDE secondary to levofloxacin was first reported by Vetrichevvel TP in 2012. Dermatomal distribution of FDE in our case has been contemplated with FDE to cephazolin occurring along the S1 nerve root and FDE to trimethoprim occurring along the C8 dermatome. The linearity of FDE may be related to the distribution of dermatome as seen with our case. Other postulated theories for linear FDE along the dermatome are blaschko lines, tension lines, Koebner phenomenon after injury, insect bite, and immune response to previously unrecognized/subclinical herpes zoster infection representing as an isotopic phenomenon. The diagnosis of FDE mainly depends upon the clinical features and temporal correlation with the intake of drugs. The oral provocation test is the most reliable diagnostic test. Histopathology of bullous FDE reveals degeneration of basal layer, pigmentary incontinence, scattered necrotic keratinocytes in the epidermis, and formation of bullae with characteristic lichenoid lymphocytic infiltrates. Treatment includes stopping offending drugs with oral and topical steroids, emollients, and oral antihistamines. Our case was treated effectively with only topical corticosteroid-antibiotic preparation and emollients. We report this case because of its rarity and to create awareness about unusual dermatological ADRs to commonly used antibiotics.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tripathi K. Adverse drug effects. In: Tripathi KD, editor. Essential of Medical Pharmacology. 7th
ed. New Delhi: Jaypee Brothers Medical Publishers; 2013. p. 82-92.
Jeevanagi SR, Manjunath S, Wali VK. A case of ciprofloxacin-induced erythema multiforme. Indian J Pharmacol 2008;40:45-6.
] [Full text]
Kawada A, Hiruma M, Morimoto K, Ishibashi A, Banba H. Fixed drug eruption induced by ciprofloxacin followed by ofloxacin. Contact Dermatitis 1994;31:182-3.
Sehgal VN, Srivastava G. Fixed drug eruption (FDE): Changing scenario of incriminating drugs. Int J Dermatol 2006;45:897-908.
Chatterjee S, Ghosh AP, Barbhuiya J, Dey SK. Adverse cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol 2006;38:429-31. [Full text]
Rönnau AC, Sachs B, von Schmiedeberg S, Hunzelmann N, Ruzicka T, Gleichmann E, et al
. Cutaneous adverse reaction to ciprofloxacin: Demonstration of specific lymphocyte proliferation and cross-reactivity to ofloxacin in vitro. Acta Derm Venereol 1997;77:285-8.
Mandal B, Steward M, Singh S, Jones H. Ciprofloxacin-induced toxic epidermal necrolysis (TEN) in a nonagerian: A case report. Age Ageing 2004;33:405-6.
Hällgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: A review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol 2003;4:267-9.
Bose SK. Ciprofloxacin-induced bullous fixed drug eruption. Indian J Dermatol Venereol Leprol 1995;61:238-9.
] [Full text]
Ada S, Yilmaz S. Ciprofloxacin-induced generalized bullous fixed drug eruption. Indian J Dermatol Venereol Leprol 2008;74:511-2.
] [Full text]
Jain SP, Jain PA. Bullous fixed drug eruption to ciprofloxacin: A case report. J Clin Diagn Res 2013;7:744-5.
Ravishankar M, Deepika G, Shwetha S. Ciprofloxacin induced fixed drug eruption. Int J Basic Clin Pharmacol 2014;3:1096-7.
Nair PA. Ciprofloxacin induced bullous fixed drug reaction: Three case reports. J Family Med Prim Care 2015;4:269-72.
] [Full text]
Kara H, Cathryn S, Neil S. Cutaneous reaction to drugs. In: Sewon K, Masayuki A, Anna L B, Alexander EH, David MJ, Amy MJ, et al
. Fitzpatrick's Dermatology. 9th
ed. New York: Mc Graw Hill Publishers; 2019. p. 754.
Vetrichevvel TP, Sudha R, Shobana S, Anandan S. Zosteriform fixed drug eruption to Levofloxacin. Indian J Dermatol 2012;57:327-8.
] [Full text]
Ozkaya-Bayazit E, Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol 1997;137:1028-9.
Ozkaya E. Fixed drug eruption: State of the art. J Dtsch Dermatol Ges 2008;6:181-8.
[Figure 1], [Figure 2], [Figure 3], [Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 1]